Evelo Biosciences
About Evelo Biosciences
The gut is a central organ of the immune system which controls immunity and inflammation through its interactions with microbes in the small intestine
We are developing a new class of oral biologic therapies that engage immune cells in the small intestine to transmit effects throughout the body
Modulation of this “gut-body network" has therapeutic potential in many major diseases
For general inquiries contact: info@evelobio.com
For media inquiries contact: media@evelobio.com
For investor inquiries contact: ir@evelobio.com
NASDAQ EVLO
122 articles about Evelo Biosciences
-
Evelo Biosciences to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
6/16/2020
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that management will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd at 11:00 a.m. ET.
-
Evelo Biosciences to Present at Jefferies 2020 Virtual Healthcare Conference
5/28/2020
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that management will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4th at 4:30 p.m. ET.
-
Evelo Biosciences Reports First Quarter Financial Results and Business Highlights
5/11/2020
Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020
-
Clinical Catch-Up: May 4-8
5/11/2020
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look. -
Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
5/7/2020
Evelo Biosciences, Inc., Rutgers University, and Robert Wood Johnson University Hospital announced the submission of an Investigational New Drug application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19.
-
Evelo Biosciences, along with Rutgers University and Robert Wood Johnson University Hospital, is driving toward a Phase II study of an investigational treatment for hospitalized patients with newly diagnosed COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
-
Evelo Biosciences to Report First Quarter 2020 Financial Results on Monday, May 11, 2020
5/4/2020
Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020 to report its first quarter 2020 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international
-
Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex
4/15/2020
Evelo Biosciences, Inc. announced the appointment of biopharmaceutical industry veteran Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer and a member of the Evelo Executive Team.
-
Evelo Announces Issuance of U.S. Patent Covering Use of Proprietary Bifidobacterium animalis ssp. lactis Strain for Treating Cancer
3/5/2020
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,576,111, entitled “Method of treating cancer using Bifidobacterium animalis ssp. lactis strain PTA-125097.
-
Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
3/2/2020
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial showed marked activity on multiple individual systemic markers of inflammation, including interleukin-6 (IL-6) and interleukin-8 (IL-8).
-
Evelo Biosciences to Present at 40th Annual Cowen Health Care Conference
2/25/2020
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 40th Annual Cowen Health Care Conference on Tuesday, March 3rd at 12:00pm EST.
-
Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
2/13/2020
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the fourth quarter and full year 2019.
-
Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
2/6/2020
Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. EST on Thursday, February 13, 2020 to report its fourth quarter and full year 2019 financial results and discuss business highlights.
-
Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration
1/10/2020
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today provided an update on recent positive regulatory interactions on the EDP1815 Phase 2 trial design, resulting in a reduction in the overall development plan timeline to registration.
-
Evelo Biosciences Appoints Juan Andres to Board of DirectorsIndustry veteran brings expertise in manufacturing, R&D, and operations from leadership roles at Novartis, Eli Lilly, and Moderna
12/5/2019
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Juan Andres to its Board of Directors.
-
Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference
11/13/2019
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the Stifel 2019 Healthcare Conference on Wednesday, November 20th at 2:25pm EST.
-
Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
11/8/2019
Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology program, EDP1503, will be presented during the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 6–10, 2019 in National Harbor, Maryland.
-
Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial
11/5/2019
Evelo Biosciences announced positive interim clinical data in an ongoing Phase 1b trial in individuals with mild to moderate psoriasis treated with a high dose of EDP1815, its clinical candidate for the treatment of a range of inflammatory diseases.
-
Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results
11/5/2019
Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced third quarter 2019 financial results.